论文部分内容阅读
使用杂交瘤技术产生单克隆抗体(1975,k(?)hler 与Milstein)为临床免疫诊断与治疗开辟了广阔的前景。自70年代后期以来,不少作者以杂交瘤技术产生单克隆抗体,试图能找到针对癌细胞表面特异抗原(tumour speci-fic antigen)的单克隆抗体,以利于肿瘤早期诊断与治疗。然而迄今为止成功的例子尚为数不多。1979年,Koprowski 等用杂交瘤技术产生了针对结肠癌细胞的单克隆抗体。其中之一,命名为1116 NS 19-9,被认为系针对肠胃腺癌表面特异抗原的,能与碳水化合物抗原
The use of hybridoma technology to produce monoclonal antibodies (1975, k (?) Hler and Milstein) for clinical immunodiagnosis and treatment has opened up a broad prospect. Since the late 1970s, many authors have developed monoclonal antibodies based on hybridoma technology in an attempt to find monoclonal antibodies against tumor specific speci-fic antigens to facilitate the early diagnosis and treatment of tumors. However, the number of successes so far is still small. In 1979, Koprowski and others used hybridoma technology to produce monoclonal antibodies against colon cancer cells. One of them, named 1116 NS 19-9, is considered to be specific for gastrointestinal adenocarcinoma-specific surface antigens and is capable of interacting with carbohydrate antigens